Neoreviews Subscribe to Pediatrics in Review
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 8 No. 2, February 2007
Right arrow E-Letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-Letters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keren, R.
Right arrow Articles by Bhutani, V. K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Keren, R.
Right arrow Articles by Bhutani, V. K.

NeoReviews Vol.8 No.2 2007 e68
© 2007 American Academy of Pediatrics

Predischarge Risk Assessment for Severe Neonatal Hyperbilirubinemia

Ron Keren, MD, MPH*
Vinod K. Bhutani, MD{dagger}

* Division of General Pediatrics, Children’s Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pa
{dagger} Department of Pediatrics, Division of Neonatal and Developmental Medicine, Stanford University School of Medicine, Stanford, Calif

Current approaches to identifying infants at risk of developing severe neonatal hyperbilirubinemia include use of an hour-specific bilirubin nomogram that employs predischarge bilirubin measurements and clinical risk factor assessment that employs multiple factors in clinical prediction rules. Determining the hour-specific total serum bilirubin before discharge has been shown to be the most accurate method for assessing risk of severe hyperbilirubinemia. Combining clinical risk factors and predischarge bilirubin values may offer additional predictive performance above either approach used alone. Current risk assessment strategies need to be validated prospectively in a large and diverse newborn population, and the risk assessment strategies should be paired with recommended actions. Finally, transcutaneous bilirubin and end-tidal carbon monoxide measurements and screening for specific genetic markers of neonatal hyperbilirubinemia have the potential to refine risk assessment strategies further.






HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Academy of Pediatrics.